ARS Pharma rises after Japan nod for neffy nasal spray for allergy

2025-09-19 08:34:22 ET

More on ARS Pharmaceuticals, Alfresa Holdings Corporation

• ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
• ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
• ARS Pharmaceuticals: 'Betting On The Come'
• ARS Pharma drops 9% as Lupin files application for generic neffy
• ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets

Read the full article on Seeking Alpha

For further details see: